LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a Read More
LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a Read More
LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a Read More
LONDON (Alliance News) - Avacta Group PLC on Monday said it has appointed Sam Williams as a non-executive director with immediate effect.The biotechnology company said Williams is currently Read More
LONDON (Alliance News) - Avacta Group PLC on Thursday said IP Group PLC now holds 17.2% stake in the biotechnology company following a transaction on December 18.Prior to that, IP holding Read More
LONDON (Alliance News) - Reagents developer Avacta Group PLC on Wednesday appointed Jose Saro as chief medical officer to lead the firm's therapeutic development strategy.Saro brings 20 Read More
LONDON (Alliance News) - IP Group PLC on Monday said its portfolio company Avacta Group PLC signed a development & license deal with LG Chem Life Sciences.IP Group currently holds a in Read More
LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to progress Affimer.The reagents developer a Read More
LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction on Tuesday.FIL lowered its holding to a Read More
LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company.In a transaction on Tuesday, Lombard to Read More
